In a noteworthy advancement for the field of mental health treatment, BrainsWay Ltd. (NASDAQ & TASE: BWAY), a prominent player in non-invasive brain disorder therapies, unveiled positive independent pilot data from a study conducted at Stanford University. This research evaluates an accelerated protocol using the company’s sophisticated Deep Transcranial Magnetic Stimulation (TMS) technology tailored specifically for patients battling Alcohol Use Disorder (AUD). The outcomes, published in the esteemed journal Brain Stimulation , spotlight the effectiveness of this innovative approach and its potential to revolutionize AUD treatment.
Accelerated Deep TMS for Alcohol Use Disorder
The pilot study, en
Comments